secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001404644-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene doses multiple participants in Embolden Rett trial; interim data mid-2026
--------------------------------------------------------------------------------

- Dosed multiple participants in Embolden registrational trial in Q4 2025; expect to complete dosing Q2 2026.
- Plan to present interim Phase 1/2 data (8 pediatric, 2 adolescent/adult) with >=12-month follow-up mid-2026.
- Cash runway through Q1 2028; early commercial-readiness activities underway including payor research.
- Initiated 13 U.S. clinical trial sites; presenting at J.P. Morgan Healthcare Conference on Jan 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/0001404644-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/ngne-20250811_d2.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer